MENU
 

PRE TAX NTA |$3.53

Value as at close of business on 7 March 2025

Advancing Medicine Is In Daniel MacArthur’s DNA

Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Based in Boston as co-director of the Medical and Population Genomics Program at the Broad Institute for Mendelian Genomics at MIT and Harvard, his work in the US had involved using new genomic technologies to help predict and diagnose diseases.

It included overseeing a team that built one of the largest genetic data bases ever assembled, collecting data from more than 140,000 people.

MacArthur saw the new centre – a joint initiative of the Garvan Institute in Sydney and the Murdoch Children’s Institute in Melbourne – as the chance to bring his years of expertise in genomic medicine back to Australia.

“The centre’s focus is applying a lot of the lessons we had learned in the early days in building the field of genomic medicine, particularly in places like the US and the UK, and applying it in the context of the Australian community,” MacArthur says.

MacArthur will outline his ­vision for genomic medicine in Australia at the Sohn Hearts & Mind Conference in Sydney on Friday.

The conference, which features top fund managers from Australia and around the world giving their best stock tips, has raised $60m for medical research in Australia since it began in 2016.

This is the first year that The Centre for Population Genomics, which has been funded from a combination of government grants and philanthropy, will receive funding from the conference.

MacArthur says his aim at the conference will be to explain the potential of the developing field of genomic medicine in Australia, adding that it is “an exciting time for the field”.

While genetics involves the study of how a person’s genes can cause a disease or an illness, the newer field of genomics involves the study of all of a person’s genes – the genome – looking at how the combination of genetic factors and environment can cause disease.

“All conditions, including the big killers like heart disease and cancer, have a contribution from both our DNA and the environment,” MacArthur says.

“If we can better understand the DNA component, it makes it a lot easier for us to identify the ­people who are most at risk of those conditions and give them the information they might need to make lifestyle changes, and also to think about how we might be able to develop therapies which could reduce the risk of those ­conditions.”

MacArthur’s work has included understanding the basis of certain rare genetic disorders, which can cause diseases such as muscular dystrophy and which particularly affect children.

Working in Boston, he oversaw a program that sequenced and analysed genomic data from more than 10,000 people from families with rare diseases – work that contributed to the discovery of more than 100 new rare disease genes.

‘We can now think about making precise changes to someone’s DNA’

Daniel MacArthur, genomic scientist

But Australia’s racial mix – which includes many people from Asia, the Middle East and South Pacific – is very different to that in the European nations that have provided the basis for a lot of genomic medicine research to date.

“My driving purpose with the centre is thinking about ways we can make sure the benefit of new technologies is available to all Australians, regardless of their background,” MacArthur said.

“We are focused on working directly with communities to build up a better picture of the patterns of genetic variation that exist within the Australian community and use it to predict and build better tools for the diagnosis, prediction and treatment of ­disease.”

When MacArthur left Australia, in 2007, after completing his PhD in human genetics at the University of Sydney, there was little work being done in the field of genomics. “But since then, there has been a huge amount of work to build up the infrastructure and the approaches to it,” he says.

“The centre, is a partnership between two different institutions in Sydney and Melbourne, is a new approach to bringing together genetic information at a very large scale in a way which can benefit Australian communities, not just the ones that are already being studied in other places around the world.”

MacArthur is based in Sydney and oversees a team that has members in Sydney, Melbourne and New Zealand.

One of his goals is to build a ­genomic data base from about 10,000 people from specific groups in Australia, including people from the Pacific, Southeast Asia, the Middle East and East ­Africa, to help study diseases in those populations.

“More than a quarter of Australian citizens were born overseas and more than half have at least one parent born overseas,” he says. “It is essential we have a genetic resource which is fit for purpose in our own country, which captures the full spectrum of diversity which exists here.”

He says the study of genomic medicine is now taking off as a result of a combination of factors including a sharp drop in the cost of the technology involved.

“The first human genome, which took about 10 years to ­sequence by a team of scientists around the world, was released in 2003, and took about $3bn to generate,” he says. “These days we can sequence a genome for less than $1000. It takes a week and is more accurate than the genome we generated back in 2003.

“It is an almost unprecedented drop in the cost of the technology which allows us to think about ­applying genomics to so many people around the world and so many patients.”

Big advances in data science such as cloud computing and the broader availability of artificial intelligence have also allowed for much easier processing of huge amounts of data.

“These technologies are now the key factor in our ability to make sense of the data and use it to diagnose, predict and treat disease,” MacArthur says.

There have also been big advances in the drugs and therapeutics available to treat diseases.

“It means we can now think about making precise changes to someone’s DNA in ways which can help cure their condition, or even potentially prevent a condition that they might go on to develop in future,” MacArthur says.

The Australian is a media partner of Sohn Hearts & Minds. You can watch Prof Daniel MacArthur's presentation from the event here.


This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Recent Posts

Read the latest insights
A curated list of HM1 investor updates, portfolio news and other interesting articles.
Read More
Reporting Season Insights: HM1 Core Portfolio Holdings
We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.
The investing megatrends you can’t ignore (and some you should rethink)
James Marlay of Livewire sat down with Vihari Ross of Antipodes (HM1 Conference Fund Manager) and James Tsinidis of Munro Partners (HM1 Core Fund Manager) to discuss the biggest megatrends shaping the future.
2025: Where to Find Market Opportunities
There are opportunities abound for investors with an active management mindset in 2025. Get more insights from one of HM1's Core Fund managers, Magellan.
Significant increase in profit and increased fully franked dividend
We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.
 

Reporting Season Insights: HM1 Core Portfolio Holdings

We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.

Read More
March 10th, 2025
 

The investing megatrends you can’t ignore (and some you should rethink)

James Marlay of Livewire sat down with Vihari Ross of Antipodes (HM1 Conference Fund Manager) and James Tsinidis of Munro Partners (HM1 Core Fund Manager) to discuss the biggest megatrends shaping the future.

Read More
March 3rd, 2025
 

2025: Where to Find Market Opportunities

There are opportunities abound for investors with an active management mindset in 2025. Get more insights from one of HM1's Core Fund managers, Magellan.

Read More
February 25th, 2025
 

Significant increase in profit and increased fully franked dividend

We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.

Read More
February 20th, 2025
 

Magellan's Elisa Di Marco - 3 Trends That Will Define The Next Decade

Elisa Di Marco of Magellan (HM1 Core Fund Manager) joined Equity Mates to unpack 3 big megatrends shaping our world today (and how we can invest in them).

Read More
February 7th, 2025
 

Nine top stock picks to prepare your portfolio for 2025

Health care, ride-sharing, and the emerging world of YouTube entertainers are among the industries leading investors have picked for growth in 2025.

Read More
January 21st, 2025
 

Resources fundies reveal top picks ahead of ‘stellar’ 2025

Some of Australia’s biggest resources funds are gearing up for a bumper start to the new year.

Read More
January 6th, 2025
 

Qiao Ma: finding killer companies, surviving the GFC & why founders win

Qiao Ma, Portfolio Manager of the Munro Partners joins Owen Rask on The Australian Investors Podcast.

Read More
January 6th, 2025
 

10 top fund managers reveal their long-term stock picks

With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. 

Read More
December 28th, 2024
 

Rikki Bannan – Don’t get caught up in momentum

Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.

Read More
December 19th, 2024
 

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
December 10th, 2024
 

Nick Griffin – The Nvidia story is not over

Nick Griffin, Founding Partner & Chief Investment Officer of Munro Partners joined the Equity Mates podcast in their Summer Series.

Read More
December 9th, 2024
 

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
December 5th, 2024
 

How Trump will impact equity markets

The United States has spoken. President Trump has returned to the White House. But how can we cut through the noise to reveal the investment, economic and geopolitical ramifications?

Read More
November 26th, 2024
 

Trump unifies top investors in decade-long bullish outlook for US

Nick Moakes, CIO of the $72 billion Wellcome Trust, told the conference that too many investors were banking on a return to the ultra-low interest rates that prevailed over the past decade.

Read More
November 20th, 2024
 

These rock-star stock picks could get markets talking next year

Eleven rock stars of international and local funds management took to stage – each tasked with picking and pitching one company whose shares will take off over the next year.

Read More
November 18th, 2024
 

Is anyone brave or stupid enough to bet against America?

Stock pickers have been punished for betting against the US. The choice between consensus and contrarianism on American exceptionalism is now harder than ever.

Read More
November 17th, 2024
 

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

Read More
November 15th, 2024
 

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Read More
November 15th, 2024
 

AI start-ups a threat to incumbent big companies

Paul Bassat predicts emerging artificial intelligence companies will disrupt sectors and overtake established incumbent companies just as rapidly as the seismic shifts that took place when the internet emerged in the mid-1990s.

Read More
November 15th, 2024
 

Howard Marks and Sohn’s big stars reveal seven rules for investing

Among the stock picks and stunts at the Sohh Hearts & Minds event, Howard Marks and Nick Moakes provided investors with long-term rules for playing markets.

Read More
November 15th, 2024
 

Sohn investors position for bullish but bumpy Trump ride

Australia and the rest of the world must adjust to a new Trump presidency that will deliver an expected bull market but also disruption, with the leader in waiting prepared to “create pain” to get his way.

Read More
November 15th, 2024
 

Sohn stock picker experts name best shares to invest in for year ahead

‍Don’t overlook down and out silver miners, legacy skincare brands ready for a revival and a big financial company suffering from a severe case of shareholder wealth destruction.

Read More
November 15th, 2024
 

Eleven stock tips from Sohn to get you through 2025

“There’s no finer place for the finance festival than in the festival city,” said Matthew Grounds. He, along with fellow Barrenjoey co-executive chairman Guy Fowler and investor Gary Weiss, is one of Sohn’s driving forces.

Read More
November 15th, 2024
 

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
November 14th, 2024
 

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
November 9th, 2024
 

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
November 6th, 2024
 

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
November 5th, 2024
 

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
November 5th, 2024
 

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
November 5th, 2024